摘要
目的探讨β联蛋白、淋巴样增强因子1在恶性黑素瘤中的表达及意义。方法采用免疫组化PowerVisionTM二步法检测25例皮内痣、45例恶性黑素瘤中β联蛋白、淋巴样增强因子1的表达情况。结果β联蛋白在恶性黑素瘤中异常表达率为73％,皮内痣为36％,两组差异有统计学意义;淋巴样增强因子1在恶性黑素瘤中阳性表达率为62．2％,皮内痣组为0,两组差异有统计学意义。肿瘤组织中淋巴样增强因子1高表达率与淋巴结转移、TNM分期密切相关(P<0．05),而β联蛋白异常表达率与淋巴结转移及TNM分期无明显关系;β联蛋白异常表达与淋巴样增强因子1高表达之间存在正相关 (P<0．05)。结论β联蛋白、淋巴样增强因子1异常表达可能与恶性黑素瘤发病相关。
Objective To investigate β-catenin and lymphoid enhancing factor 1 （LEF-1） expression in malignant melanoma. Methods β-catenin and LEF-1 protein expression was examined using the PowerVision^TM immunohistochemical method in 25 cases of intradermal nevus and 45 cases of malignant melanoma. Results Comparing malignant melanoma with intradermal nevi, there was a significant difference in the expression of β-catenin （33/45=73% vs. 9/25 = 36%, respectively; P〈0.05） and the expression of LEF-1 （28/45 =62.2% vs. 0/25 = 0%, respectively; P〈0.05）. LEF-1 expression was correlated with lymphatic metastasis and TNM staging （P〈0.05）, while β-catenin expression was not. In cancer tissues, the abnormal expression of β-catenin was positively correlated with LEF-1 expression （P〈0.05）. Conclusion The abnormal expression of β-catenin and LEF-1 may play an important role in the carcinogenesis and progression of malignant melanoma.
出处
《中华皮肤科杂志》
CAS
CSCD
北大核心
2005年第11期665-667,共3页
Chinese Journal of Dermatology
